These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36455646)

  • 1. Considerations in assessing the abuse potential of psychedelics during drug development.
    Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D
    Neuropharmacology; 2023 Feb; 224():109352. PubMed ID: 36455646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.
    Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; Zia FZ
    Neuropharmacology; 2022 Nov; 218():109220. PubMed ID: 35987353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.
    Heal DJ; Gosden J; Smith SL; Atterwill CK
    Neuropharmacology; 2023 Mar; 225():109375. PubMed ID: 36529260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
    Johnson MW; Griffiths RR; Hendricks PS; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():143-166. PubMed ID: 29753748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.
    Henningfield JE; Ashworth J; Heal DJ; Smith SL
    J Psychopharmacol; 2023 Jan; 37(1):33-44. PubMed ID: 36588452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP; Ng L; Erritzoe D; Knudsen GM; Nichols CD; Nichols DE; Pani L; Soula A; Nutt D
    J Psychopharmacol; 2019 Sep; 33(9):1039-1057. PubMed ID: 31303095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A regulatory perspective on the evaluation of hallucinogen drugs for human use.
    Calderon SN; Hunt J; Klein M
    Neuropharmacology; 2018 Nov; 142():135-142. PubMed ID: 29180224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the 5-HT
    Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A
    J Neurosci; 2023 Nov; 43(45):7472-7482. PubMed ID: 37940583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
    Bender D; Hellerstein DJ
    Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The varieties of psychedelic law.
    Marks M
    Neuropharmacology; 2023 Mar; 226():109399. PubMed ID: 36565855
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.